How much funding has Autobahn Therapeutics raised?

Autobahn Therapeutics has raised $208.7M in total funding, most recently a Series C round.

Who are Autobahn Therapeutics's investors?

Autobahn Therapeutics's investors include ARCH Venture Partners, Cowen Healthcare Investments, Newpath Management, Biogen, Bristol Myers Squibb, Pfizer Ventures.

When was Autobahn Therapeutics founded?

Autobahn Therapeutics was founded in 2017.

Where is Autobahn Therapeutics headquartered?

Autobahn Therapeutics is headquartered in San Diego, California, United States.

What industry is Autobahn Therapeutics in?

Autobahn Therapeutics operates in Life Sciences.

How many employees does Autobahn Therapeutics have?

Autobahn Therapeutics has 11-50 employees.

Autobahn Therapeutics

Improving life health for people affected by CNS disorders

San Diego, United States · Founded 2017 · $208.7M raised

Life Sciences

Headquarters: San Diego, California
Employees: 11–50
Founded: 2017
Business Model: B2B

Website: autobahntx.com
Total Funding: $208.7M
Last Round: $100.0M Series CJul 2024
Rounds: 3

About

Autobahn Therapeutics is a clinical-stage biotechnology company developing next-generation medications for central nervous system (CNS) disorders, including neuropsychiatric and neuroimmunologic conditions. Its lead candidate ABX-002 is a thyroid hormone receptor beta agonist in Phase 2 trials for bipolar depression, guided by a brain-targeting chemistry platform and biomarker-driven development.

Summary

Autobahn Therapeutics is a Life Sciences company based in San Diego, United States, founded in 2017. It has raised $208.7M in total across 3 rounds, most recently a $100.0M Series C round in Jul 2024. Investors include ARCH Venture Partners, Cowen Healthcare Investments and Newpath Management.